VEGFA

Oncogene
Vascular endothelial growth factor A, long form UniProt accession P15692

Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity)

Source: UniProt

Homodimer; disulfide-linked (By similarity). Also found as heterodimer with PGF (By similarity). Interacts with NRP1 (PubMed:26503042).

Interacts with isoform 2 of BSG (PubMed:25825981). Interacts with CD82; this interaction inhibits VEGFA-mediated signaling pathway (PubMed:34530889)

Source: UniProt
Cytoplasm, Nucleus Secreted Endoplasmic reticulum, Golgi apparatus, Secreted, extracellular space, extracellular matrix Secreted Secreted Secreted
Source: UniProt

Higher expression in pituitary tumors than the pituitary gland

Widely expressed

Widely expressed

Widely expressed

Not widely expressed

Not widely expressed

Source: UniProt
  • Microvascular complications of diabetes 1 (MVCD1)

    Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults.

    It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

Source: UniProt

Click a pathway to open the interactive Reactome viewer.

Pathway list and interactive viewer: Reactome

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to VEGFA, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 384

NCT ID Condition Brief Title Phase Status
NCT04902690 Multiple Sclerosis Relapse The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients N/A UNKNOWN
NCT06542796 Hepatocellular Carcinoma, Immunotherapy Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma NA RECRUITING
NCT00659555 Macular Degeneration Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops PHASE1 COMPLETED
NCT00728598 Proliferative Diabetic Retinopathy, Angiogenesis Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis N/A COMPLETED
NCT01249521 Metastatic Colorectal Cancer Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer PHASE2 UNKNOWN
NCT02606019 Dengue The Use of Biomarkers in Predicting Dengue Outcome N/A UNKNOWN
NCT04970251 Intraocular Pressure, Neovascular Glaucoma, Vascular Endothelial Growth Factor Overexpression, Glaucoma Secondary to Eye Inflammation Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma NA COMPLETED
NCT00216814 Bladder Cancer Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic Factors N/A TERMINATED
NCT04964089 Wet Age-related Macular Degeneration A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) PHASE3 COMPLETED
NCT06243406 Choroidal Neovascularization Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization N/A UNKNOWN